Analystreport

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $35.00 price target on the stoc

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com